369 related articles for article (PubMed ID: 27715380)
41. Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients.
Davatchi F; Nikbin B; Shams H; Sadeghi Abdollahi B; Mohyeddin M; Shahram F
Int J Rheum Dis; 2013 Apr; 16(2):139-47. PubMed ID: 23773637
[TBL] [Abstract][Full Text] [Related]
42. [Eye and Behçet's disease].
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Jun; 42(6):626-641. PubMed ID: 31164292
[TBL] [Abstract][Full Text] [Related]
43. Behçet's syndrome: ocular features in an Australian population.
Wakefield D; McCluskey P
Aust N Z J Ophthalmol; 1990 May; 18(2):129-35. PubMed ID: 2390239
[TBL] [Abstract][Full Text] [Related]
44. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
45. Characteristics, Etiology, and Clinical Outcome of Retinal Vasculitis in Tertiary Hospital in Thailand.
Vongkulsiri S; Vanichseni S; Choontanom R; Keorochana N
Ocul Immunol Inflamm; 2024 Feb; 32(2):218-225. PubMed ID: 36731516
[TBL] [Abstract][Full Text] [Related]
46. Retinal tears associated with panuveitis and Behçet's disease.
Akova YA; Yilmaz G; Aydin P
Ophthalmic Surg Lasers; 1999; 30(9):762-5. PubMed ID: 10574500
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.
Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F
Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845
[TBL] [Abstract][Full Text] [Related]
48. Behcet's disease: systemic and ocular manifestations.
Paovic J; Paovic P; Sredovic V
Biomed Res Int; 2013; 2013():247345. PubMed ID: 24199188
[TBL] [Abstract][Full Text] [Related]
49. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects.
Mishima S; Masuda K; Izawa Y; Mochizuki M; Namba K
Trans Am Ophthalmol Soc; 1979; 77():225-79. PubMed ID: 397657
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
51. Pars plana vitrectomy for ocular complications of Behçet's disease.
Sullu Y; Alotaiby H; Beden U; Erkan D
Ophthalmic Surg Lasers Imaging; 2005; 36(4):292-7. PubMed ID: 16156145
[TBL] [Abstract][Full Text] [Related]
52. Frosted branch angiitis as ocular manifestation of Behçet's disease: unusual case report and literature review.
Kwon SJ; Park DH; Shin JP
Korean J Ophthalmol; 2013 Dec; 27(6):466-9. PubMed ID: 24311935
[TBL] [Abstract][Full Text] [Related]
53. Inter-observer Variability in Scoring Ultra-wide-field Fluorescein Angiography in Patients with Behçet Retinal Vasculitis.
Moon SW; Kim BH; Park UC; Yu HG
Ocul Immunol Inflamm; 2017 Feb; 25(1):20-28. PubMed ID: 27230121
[TBL] [Abstract][Full Text] [Related]
54. Reconstitution of disrupted photoreceptor layer in uveitis associated with Behçet's disease by infliximab treatment.
Takeuchi M; Harimoto K; Taguchi M; Sakurai Y
BMC Ophthalmol; 2015 Dec; 15():177. PubMed ID: 26653575
[TBL] [Abstract][Full Text] [Related]
55. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
56. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
57. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease.
Kaburaki T; Araki F; Takamoto M; Okinaga K; Yoshida A; Numaga J; Fujino Y; Kawashima H
Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):709-14. PubMed ID: 19997745
[TBL] [Abstract][Full Text] [Related]
58. Uveitis in Behçet disease: an analysis of 880 patients.
Tugal-Tutkun I; Onal S; Altan-Yaycioglu R; Huseyin Altunbas H; Urgancioglu M
Am J Ophthalmol; 2004 Sep; 138(3):373-80. PubMed ID: 15364218
[TBL] [Abstract][Full Text] [Related]
59. Comparison of Spectral Domain Optical Coherence Tomography (SD OCT) Findings with Laser Flare Photometry (LFP) Measurements in Behçet's Uveitis.
Işık MU; Yalcındag N
Ocul Immunol Inflamm; 2020; 28(2):194-199. PubMed ID: 30556759
[No Abstract] [Full Text] [Related]
60. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
